⏳ The deadline is approaching! There is still time to submit your application for the 2026 ISLB Grants. The International Society of Liquid Biopsy (ISLB) is awarding a total of $50,000 USD across two incredible funding opportunities to accelerate advancements in non-invasive diagnostics. Are you an early-career scientist or part of an innovative research team? We want to hear from you! 🔬 The Rabab Gaafar Young Investigator Grant: $25,000 USD to support early-career scientists in their postdoctoral stage. 💡 The Garcia-Puche Grant for Innovation: $25,000 USD to support researchers and entrepreneurs developing technologies for faster, more accurate diagnostics. 🗓️ Submit your proposal by September 20, 2026. Secure funding for your ongoing research today. Find full details and application portals below: 🔗 Rabab Gaafar Grant: islb.info/islb-investigator-…🔗 Garcia-Puche Grant: islb.info/islb-innovation-gr… #LiquidBiopsy #ResearchGrants #MedicalInnovation #ISLB #CallForProposals #OncologyFunding #FutureOfMedicine @drgandara @ChristianRolfo @UmbertoMalapel1 @ElJanLe

Find out what awaits at the 8th Annual Congress of Liquid Biopsy in Madrid. Across three days of scientific exchange, ISLB 2026 will bring together the liquid biopsy community to explore the latest research, emerging technologies and clinical applications shaping the field. Programme activities will include (but not limited to): 🔹 Expert-led workshops & sessions exploring evolving methodologies and clinical applications 🔹 Oral abstract sessions showcasing important new research and findings 🔹 Dedicated poster sessions and a guided poster tour designed to encourage discussion, feedback and collaboration These activities form part of a broader programme covering circulating tumour cells, tumour-derived vesicles, RNA, proteomics, tumour-specific research, industry-supported sessions and much more. Join researchers, clinicians and industry experts in Madrid for meaningful scientific exchange and new opportunities to connect. 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗮𝗻𝗱 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿 → islb-congress.info #ISLB2026 #LiquidBiopsy #CancerResearch #PrecisionOncology #ClinicalResearch #ScientificCongress #Madrid

🏆 Congratulations to Dr. Natasha Leighl, recipient of the ISLB 2026 Gandara Clinical Research Award. Dr. Leighl is Division Head of Medical Oncology and Hematology at Princess Margaret Cancer Centre and the UHN-Sinai Health Department of Medicine, Daniel E. Bergsagel Chair in Medical Oncology, and Professor at the University of Toronto. An internationally recognized leader in lung cancer precision medicine, diagnostics, clinical management, and drug development, Dr. Leighl has made transformative contributions to advancing patient care worldwide. Her pioneering work in international clinical trials, new drug development, and the implementation of liquid biopsy in clinical practice has helped shape the future of lung cancer diagnosis and treatment. With more than 450 peer-reviewed publications and recognition as a Clarivate Highly Cited Researcher and ScholarGPS Highly Ranked Scholar, Dr. Leighl continues to drive innovation while mentoring the next generation of oncology leaders. In addition to her research achievements, Dr. Leighl serves on the Board of Directors of the International Association for the Study of Lung Cancer (IASLC), chairs multiple international guideline initiatives, leads the ISLB Education Committee, and serves as ISLB Secretary-Elect. We are honoured to recognize Dr. Leighl's exceptional contributions to clinical research, education, and patient care with the ISLB 2026 Gandara Clinical Research Award. 𝗟𝗲𝗮𝗿𝗻 𝗠𝗼𝗿𝗲 → islb-congress.info Please join us in congratulating Dr. Leighl on this well-deserved recognition. #ISLB2026 #GandaraClinicalResearchAward #LungCancer #ClinicalResearch #PrecisionMedicine #LiquidBiopsy #Oncology #CancerResearch

The ISLB 2026 speaker lineup is now live. Meet the innovators and rising leaders shaping this year's scientific program, each contributing a unique perspective with exceptional insights and bold ideas at the congress. These speakers represent a globally recognized group of leaders in liquid biopsy, precision oncology, molecular diagnostics, translational cancer research, and emerging biomarker technologies. Collectively, they include medical oncologists, pathologists, biostatisticians, surgeon-scientists, molecular biologists, geneticists, public health leaders, and biomedical engineers from leading institutions across North America, Europe, Asia, and Australia. Making ISLB 2026 a congress led by many of the world's foremost experts shaping the future of cancer diagnostics and personalized medicine in Liquid Biopsy. 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗹𝗶𝘀𝘁 → lnkd.in/gyWKjE9T #ISLB2026 #LiquidBiopsy #CancerResearch #PrecisionMedicine #Medicine #Cancer #Research #Science #Oncology #MolecularDiagnostics #Pathologists

𝗣𝗿𝗼𝗳. 𝗟𝘂𝗶𝘀 𝗠𝗼𝗻𝘁𝘂𝗲𝗻𝗴𝗮, Senior Researcher in 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗖𝗮𝗻𝗰𝗲𝗿 𝗕𝗶𝗼𝗹𝗼𝗴𝘆 at 𝗖𝗜𝗠𝗔 and Professor of Cell Biology at the University of Navarra, will join the #ISLB2026 speakers. His work in molecular oncology and biomarker discovery continues to advance the role of liquid biopsy in cancer diagnostics. 𝗝𝗼𝗶𝗻 𝘂𝘀 𝗶𝗻 𝗠𝗮𝗱𝗿𝗶𝗱 → islb-congress.info #ISLB2026 #LiquidBiopsy #PrecisionMedicine #CIMA #UniversityOfNavarra #CancerDiagnostics #CancerResearch #Oncology

We are excited to welcome 𝗗𝗿. 𝗝𝗲𝗻𝗻𝗮 𝗖𝗮𝗻𝘇𝗼𝗻𝗶𝗲𝗿𝗼, breast medical oncologist & translational researcher at John Hopkins, to #ISLB2026. She is a panelist on the 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗧𝘂𝗺𝗼𝗿 𝗕𝗼𝗮𝗿𝗱, bringing real-world insight to advancing liquid biopsy in breast cancer care. 𝗝𝗼𝗶𝗻 𝘂𝘀 𝗶𝗻 𝗠𝗮𝗱𝗿𝗶𝗱 → islb-congress.info #LiquidBiopsy #CancerDiagnostics #PrecisionMedicine

We are celebrating 10 years of advancing liquid biopsy. ISLB 2026 brings the medical community together in Madrid as the only leading congress dedicated to liquid biopsy. Join us this November for world-class science, collaboration and a look ahead at the next decade of medical advancements. islb-congress.info #ISLB2026 #LiquidBiopsy #CancerDiagnostics #Oncology #PrecisionMedicine

Highlights from the ISLB Workshop in Pompeii, Italy 🇮🇹 Over two days, leading experts came together to share insights, discuss innovation, and explore the future of #LiquidBiopsy across research and clinical practice. Thank you to everyone who contributed to an outstanding scientific program. 🧬 #ISLB #PrecisionOncology #CancerResearch #MolecularDiagnostics @ChristianRolfo @UmbertoMalapel1 @drgandara @LuisRaezMD @ClaraMontagut @olakhorshid @evi_lianidou @ElJanLe @MJOSESERRANO19 @RobertoBoreaMD @PasqualePisapia @DrYukselUrun @ErulEnes

🧬 Liquid Biopsy at #ESMO2025 key takeaways Liquid biopsy, especially plasma ctDNA, is no longer a concept, it’s part of daily clinical practice across multiple tumor types. ✅Driving treatment decisions with real-time molecular insights ✅Enabling escalation & de-escalation strategies (e.g. CRC) ✅Identifying patients for adjuvant immunotherapy (MIBC) ✅Expanding into early detection, risk stratification & MRD ✅Tumor-informed assays remain dominant for MRD, while new biofluids like CSF are opening additional windows into tumor biology. ⚠️ Challenges persist but so does momentum. 📌 The direction is clear: liquid biopsy is shaping the future of precision oncology, today. 🔗 Read more: journalofliquidbiopsy.com/ar… #ISLB #LiquidBiopsy #ctDNA #MRD #PrecisionOncology @UmbertoMalapel1 @ElJanLe @drgandara @MJOSESERRANO19 @ChristianRolfo @RobertoBoreaMD @LuisRaezMD @DrYukselUrun @ErulEnes @ReduzziCarol @jlb_islb @ddemiguelperez @PasqualePisapia @Al3ssandroRusso @eleonora_nicolo @DrMirallas @myESMO